FDA Suggests Revising Cannabis Classification for Medical Use

Regulations by 2FIRSTS.ai

Jan.24.2024

FDA Suggests Revising Cannabis Classification for Medical Use

The FDA has proposed reclassifying marijuana as a type III substance due to its potential medical uses, sparking widespread attention and discussion.

According to a report by the media outlet Ismorbo on January 22, the U.S. Food and Drug Administration (FDA) recently revealed that cannabis is considered to have legitimate medical uses and has proposed reclassifying it from a Schedule I substance to a Schedule III substance. This decision has sparked widespread attention and discussion.

The FDA has stated that compared to other substances classified as Schedule I or II drugs, marijuana poses a lower threat to public health. While some individuals may face risks due to excessive use of marijuana, the majority of marijuana users do not pose significant risks to themselves or others.

When assessing the risks and benefits of marijuana, the FDA has chosen to use alcohol as a reference standard, despite alcohol not being classified as a controlled substance. The agency acknowledges that there is scientific evidence supporting the use of medical marijuana in treating various symptoms, including but not limited to appetite loss, anxiety disorders, epilepsy, inflammatory bowel diseases, nausea and vomiting, pain, and post-traumatic stress disorder. However, the FDA emphasizes that this does not mean that the safety and effectiveness of marijuana have been fully established.

This proposal could provide more operational freedom for cannabis companies and alleviate tax restrictions dating back 40 years. However, the decision does not explicitly endorse the use of marijuana for treating specific health conditions. This reclassification could also stimulate further research on cannabis, opening up new possibilities for the future development of this field. The long-term impact of this decision on the cannabis industry and related sectors is being closely watched.

References:

[1] EE.UU.: La FDA recomienda a la DEA reclasificar al cannabis como una droga de menor riesgo — MOR.BO

Also Read:

[1] FDA Recommends Reclassifying Marijuana as Less Restricted Drug

[2] FDA Urged Reformation of PMTA Process

#North America #United States #Legislation #CBD #FDA #Cannabis vaporization

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Luxembourg Passes Bill 8333: Heated Tobacco and Nicotine Pouches Regulated

Luxembourg’s Chamber of Deputies adopted Bill No. 8333, transposing EU Directive 2022/2100 and extending tobacco controls to heated tobacco, e-cigarettes and nicotine pouches. The law bans flavourings, restricts sales to minors, and caps nicotine content at 0.048 mg per pouch. CBD and caffeine additives are prohibited.

Nov.03 by 2FIRSTS.ai

Malaysian state of Selangor proposes sharing e-cigarette tax revenue with federal government for local enforcement agencies

Selangor, Malaysia proposes federal government share e-cigarette tax revenues for local enforcement, suggesting collaboration for better regulation.

Oct.13 by 2FIRSTS.ai

2Firsts Observation｜Japan Tobacco Opens Ploom Counter at Dubai International Airport with Scent-Based Experience Display

2Firsts observed that Japan Tobacco’s heated tobacco brand Ploom has set up an independent retail counter at Dubai International Airport’s duty-free zone, showcasing its new Ploom AURA device. The counter features an interactive scent-release system that allows consumers to experience flavors through aroma rather than inhalation, offering a new approach to product display in smoke-free environments.

Nov.13 by 2FIRSTS.ai

Zyn Retailers to Pay $3M Settlement for Violating San Francisco’s Flavored Nicotine Ban

San Francisco’s City Attorney’s Office has reached a $3 million settlement with three online tobacco retailers accused of illegally selling flavored Zyn nicotine pouches, violating the city’s 2017 ban on flavored tobacco products.